European Innovation Council

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for targeted cancer therapies. Founded in 2015, the company has established a proprietary drug delivery platform, Sagitta®, which enables the design of targeted drug candidates for various indications. RS Research's pipeline includes several proprietary programs in different stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. In addition to drug development, RS Research offers a range of services, including preclinical absorption, distribution, metabolism, and excretion studies, bioanalytical and analytical testing, and patent consulting. The company operates a GMP-certified production facility for clinical batch drug candidates and has successfully engaged in co-development projects with international partners, showcasing its commitment to advancing cancer treatment through modern therapeutic approaches.

NanoScent Ltd is an Israeli startup established in 2017, specializing in the development of an IoT-based scent recognition platform utilizing advanced nanotechnology. The company focuses on creating innovative sensors that monitor air and water quality, ensuring compliance with environmental standards across various industries, including utilities, manufacturing, automotive, and health management. Their flagship product, VOCID® H2Confirm, is a sensor-based system designed for the hydrogen supply chain, capable of detecting impurities and volatile organic compounds in real-time. This technology provides critical monitoring capabilities, alerting users to potential contamination, thereby enhancing safety and quality control. NanoScent has successfully raised significant funding and is supported by strategic partners, reinforcing its commitment to advancing climate technology through cutting-edge sensing solutions.

Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

PlasFree is a medical device company focused on developing ClearPlasma, an innovative solution aimed at improving the treatment of massive bleeding. Founded in 2017 and based in Nazareth, Israel, PlasFree's ClearPlasma device modifies human plasma by extracting specific proteins, such as fibrinolytic proteins and pepsinogen, which play a role in blood clot dissolution. By enhancing the coagulation properties of plasma, the device enables healthcare professionals to deliver safer and more effective treatments for excessive bleeding. ClearPlasma can be integrated into conventional apheresis systems, allowing for the efficient production of plasma products tailored for critical medical situations. The company's mission is to revolutionize bleeding management and provide improved therapeutic options worldwide.

PlasFree is a medical device company focused on developing ClearPlasma, an innovative solution aimed at improving the treatment of massive bleeding. Founded in 2017 and based in Nazareth, Israel, PlasFree's ClearPlasma device modifies human plasma by extracting specific proteins, such as fibrinolytic proteins and pepsinogen, which play a role in blood clot dissolution. By enhancing the coagulation properties of plasma, the device enables healthcare professionals to deliver safer and more effective treatments for excessive bleeding. ClearPlasma can be integrated into conventional apheresis systems, allowing for the efficient production of plasma products tailored for critical medical situations. The company's mission is to revolutionize bleeding management and provide improved therapeutic options worldwide.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

NanoScent Ltd is an Israeli startup established in 2017, specializing in the development of an IoT-based scent recognition platform utilizing advanced nanotechnology. The company focuses on creating innovative sensors that monitor air and water quality, ensuring compliance with environmental standards across various industries, including utilities, manufacturing, automotive, and health management. Their flagship product, VOCID® H2Confirm, is a sensor-based system designed for the hydrogen supply chain, capable of detecting impurities and volatile organic compounds in real-time. This technology provides critical monitoring capabilities, alerting users to potential contamination, thereby enhancing safety and quality control. NanoScent has successfully raised significant funding and is supported by strategic partners, reinforcing its commitment to advancing climate technology through cutting-edge sensing solutions.

HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

NanoScent Ltd is an Israeli startup established in 2017, specializing in the development of an IoT-based scent recognition platform utilizing advanced nanotechnology. The company focuses on creating innovative sensors that monitor air and water quality, ensuring compliance with environmental standards across various industries, including utilities, manufacturing, automotive, and health management. Their flagship product, VOCID® H2Confirm, is a sensor-based system designed for the hydrogen supply chain, capable of detecting impurities and volatile organic compounds in real-time. This technology provides critical monitoring capabilities, alerting users to potential contamination, thereby enhancing safety and quality control. NanoScent has successfully raised significant funding and is supported by strategic partners, reinforcing its commitment to advancing climate technology through cutting-edge sensing solutions.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners. OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance. OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.